2024’s top general practice stories From Wegovy and Mounjaro, to tongue cancer, RSV, and vitamin B toxicity, what were the stories most read by GPs this year?
Ozempic shortage extended The manufacturer has informed the TGA that supply will be limited until 31 December 2025, with GPs labelling it an ‘ongoing disappointment’.
Study compares Mounjaro to Wegovy for weight loss A new clinical trial, sponsored by the manufacturer, found Mounjaro led to greater weight loss, but GPs warn of its ‘risks of biases’.
TGA urges ‘extreme caution’ amid fake Ozempic pen imports GPs are being warned to lookout for the counterfeit pens and are urged to inform their patients, with one person already suffering life-threatening complications.
Mounjaro expanded to include weight management The TGA has approved tirzepatide for the treatment of overweight and obesity for those with comorbidities, via private prescription.
Replica Ozempic and Mounjaro to be banned The Government has removed a loophole allowing the mass production of the compounded drugs amid growing patient safety concerns.